Multi-day maintenance of extracorporeal lungs using cross-circulation with conscious swine
Lung remains the least utilized solid organ for transplantation. Efforts to recover donor lungs with reversible injuries using ex-vivo perfusion systems are limited to less than 24 hours of support. Here, we demonstrate the feasibility of extending normothermic extracorporeal lung support to 4 days using cross-circulation with conscious swine.
ConclusionWarm retrograde perfusion can remove more fat from lung grafts with fat embolism in a porcine donor model.
We describe a case of successfully ex vivo treated and transplanted human lung allografts.MethodsDonor human lungs were assessed using ex vivo, our trouble shooting protocol allowed safe recovery.ResultsWe successfully implanted our ex vivo treated organs.
Method increases number of available lungs with comparable patient outcomes
Authors: Lightle W, Daoud D, Loor G Abstract Ex vivo lung perfusion (EVLP) represents a potentially important advancement in the preservation of donor lungs prior to transplantation. Portable EVLP or "Breathing Lung Transplantation" with the Organ Care System (OCS) Lung combines the fundamental components of EVLP with portability, thus reducing the total ischemic burden. The Food and Drug Administration (FDA) approved OCS for perfusion of standard donor lungs prior to transplant in 2018. The current review discusses the available literature on the clinical outcomes of OCS Lung as well as translational dat...
Publication date: Available online 9 October 2019Source: The Lancet Respiratory MedicineAuthor(s): Marcelo Cypel, Jordan J Feld, Marcos Galasso, Rafaela V Pinto Ribeiro, Nikki Marks, Magdalena Kuczynski, Deepali Kumar, Ilona Bahinskaya, Vanderlei S Bagnato, Cristina Kurachi, Arthur S S.sky, Jonathan C Yeung, Laura Donahoe, Marc de Perrot, Kazuhiro Yasufuku, Andrew Pierre, Matthew Binnie, Cecilia Chaparro, Tereza Martinu, Manyin ChenSummaryBackgroundA substantial proportion of organ donors test positive for hepatitis C virus (HCV) infection. To date, only a few studies have evaluated the safety of using lungs from these don...
This cohort study assesses the long-term outcomes of transplant recipients of donor lungs treated with ex vivo lung perfusion.
Limited donor lung availability and prolonged wait times remain substantial barriers to lung transplant. According to the Scientific Registry of Transplant Recipients, 11% of patients were removed from the wait-list in 2017 because of death or clinical deterioration and 40% of patients waited longer than 1 year before transplant. Ex vivo lung perfusion (EVLP) provides the opportunity to expand the donor pool, but despite encouraging early posttransplant outcomes, the long-term effect of EVLP remains unclear. In this issue of JAMA Surgery, Divithotawela et al present 10-year outcomes of the Toronto Lung Transplant Group &rs...
Current ex vivo lung perfusion (EVLP) protocols aim to achieve perfusion flows of 40% of cardiac output or more. We hypothesized that a lower target flow rate during EVLP would improve graft function and decrease inflammation of donation after circulatory death (DCD) lungs.
We present two cases of circulatory death donor (DCD) hearts recovered using NMP.
We examined these outcomes in a large-cohort, single-center series of clinical EVLP cases.